Radoslaw A Rippel1, Hossein Ghanbari, Alexander M Seifalian. 1. UCL Centre for Nanotechnology & Regenerative Medicine, Division of Surgery and Interventional Science, University College London, London, UK. r.rippel@ucl.ac.uk
Abstract
BACKGROUND: Heart valve disease is currently a growing problem, and demand for heart valve replacement is predicted to increase significantly in the future. Existing "gold standard" mechanical and biological prosthesis offers survival at a cost of significantly increased risks of complications. Mechanical valves may cause hemorrhage and thromboembolism, whereas biologic valves are prone to fibrosis, calcification, degeneration, and immunogenic complications. METHODS: A literature search was performed to identify all relevant studies relating to tissue-engineered heart valve in life sciences using the PubMed and ISI Web of Knowledge databases. DISCUSSION: Tissue engineering is a new, emerging alternative, which is reviewed in this paper. To produce a fully functional heart valve using tissue engineering, an appropriate scaffold needs to be seeded using carefully selected cells and proliferated under conditions that resemble the environment of a natural human heart valve. Bioscaffold, synthetic materials, and preseeded composites are three common approaches of scaffold formation. All available evidence suggests that synthetic scaffolds are the most suitable material for valve scaffold formation. Different cell sources of stem cells were used with variable results. Mesenchymal stem cells, fibroblasts, myofibroblasts, and umbilical blood stem cells are used in vitro tissue engineering of heart valve. Alternatively scaffold may be implanted and then autoseeded in vivo by circulating endothelial progenitor cells or primitive circulating cells from patient's blood. For that purpose, synthetic heart valves were developed. CONCLUSIONS: Tissue engineering is currently the only technology in the field with the potential for the creation of tissues analogous to a native human heart valve, with longer sustainability, and fever side effects. Although there is still a long way to go, tissue-engineered heart valves have the capability to revolutionize cardiac surgery of the future.
BACKGROUND:Heart valve disease is currently a growing problem, and demand for heart valve replacement is predicted to increase significantly in the future. Existing "gold standard" mechanical and biological prosthesis offers survival at a cost of significantly increased risks of complications. Mechanical valves may cause hemorrhage and thromboembolism, whereas biologic valves are prone to fibrosis, calcification, degeneration, and immunogenic complications. METHODS: A literature search was performed to identify all relevant studies relating to tissue-engineered heart valve in life sciences using the PubMed and ISI Web of Knowledge databases. DISCUSSION: Tissue engineering is a new, emerging alternative, which is reviewed in this paper. To produce a fully functional heart valve using tissue engineering, an appropriate scaffold needs to be seeded using carefully selected cells and proliferated under conditions that resemble the environment of a natural human heart valve. Bioscaffold, synthetic materials, and preseeded composites are three common approaches of scaffold formation. All available evidence suggests that synthetic scaffolds are the most suitable material for valve scaffold formation. Different cell sources of stem cells were used with variable results. Mesenchymal stem cells, fibroblasts, myofibroblasts, and umbilical blood stem cells are used in vitro tissue engineering of heart valve. Alternatively scaffold may be implanted and then autoseeded in vivo by circulating endothelial progenitor cells or primitive circulating cells from patient's blood. For that purpose, synthetic heart valves were developed. CONCLUSIONS: Tissue engineering is currently the only technology in the field with the potential for the creation of tissues analogous to a native human heart valve, with longer sustainability, and fever side effects. Although there is still a long way to go, tissue-engineered heart valves have the capability to revolutionize cardiac surgery of the future.
Authors: S P Hoerstrup; R Sodian; S Daebritz; J Wang; E A Bacha; D P Martin; A M Moran; K J Guleserian; J S Sperling; S Kaushal; J P Vacanti; F J Schoen; J E Mayer Journal: Circulation Date: 2000-11-07 Impact factor: 29.690
Authors: Lisa E Freed; Farshid Guilak; X Edward Guo; Martha L Gray; Robert Tranquillo; Jeffrey W Holmes; Milica Radisic; Michael V Sefton; David Kaplan; Gordana Vunjak-Novakovic Journal: Tissue Eng Date: 2006-12
Authors: Hossein Ghanbari; Helene Viatge; Asmeret G Kidane; Gaetano Burriesci; Mehdi Tavakoli; Alexander M Seifalian Journal: Trends Biotechnol Date: 2009-05-04 Impact factor: 19.536
Authors: S J McCarthy; G F Meijs; N Mitchell; P A Gunatillake; G Heath; A Brandwood; K Schindhelm Journal: Biomaterials Date: 1997-11 Impact factor: 12.479
Authors: Henryk J Salacinski; Nigel R Tai; Robert J Carson; Alan Edwards; George Hamilton; Alexander M Seifalian Journal: J Biomed Mater Res Date: 2002-02
Authors: J Koudy Williams; Elizabeth S Miller; Magan R Lane; Anthony Atala; James J Yoo; James E Jordan Journal: J Cardiovasc Transl Res Date: 2015-09-04 Impact factor: 4.132
Authors: Nafiseh Masoumi; Benjamin L Larson; Nasim Annabi; Mahshid Kharaziha; Behnam Zamanian; Kayle S Shapero; Alexander T Cubberley; Gulden Camci-Unal; Keefe B Manning; John E Mayer; Ali Khademhosseini Journal: Adv Healthc Mater Date: 2014-01-22 Impact factor: 9.933
Authors: Nicholas J Amoroso; Antonio D'Amore; Yi Hong; Christian P Rivera; Michael S Sacks; William R Wagner Journal: Acta Biomater Date: 2012-08-10 Impact factor: 8.947
Authors: Aline L Y Nachlas; Siyi Li; Rajneesh Jha; Monalisa Singh; Chunhui Xu; Michael E Davis Journal: Acta Biomater Date: 2018-03-02 Impact factor: 8.947
Authors: John D Vossler; Young Min Ju; J Koudy Williams; Steven Goldstein; James Hamlin; Sang Jin Lee; James J Yoo; Anthony Atala Journal: Biomed Mater Date: 2015-09-03 Impact factor: 3.715